BI-1622 is an orally active and highly selective HER2 (ERBB2) inhibitor with an IC50 of 7 nM; it exhibits potent in vivo antitumor efficacy in xenograft mouse models of H2170 and PC9 cells, and demonstrates favorable metabolic and pharmacokinetic properties.